{"data":{},"content":[{"data":{},"content":[{"data":{},"marks":[],"value":"Das Pharmaunternehmen ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Gilead Sciences","nodeType":"text"},{"data":{},"marks":[],"value":" ist im Einkaufsmodus. Jüngst wurde das Biotech-Unternehmen ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Arcellx ","nodeType":"text"},{"data":{},"marks":[],"value":"für 7,8 Milliarden US-Dollar gekauft. Kurz darauf folgte das Autoimmun-Startup ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Ouro Medicines","nodeType":"text"},{"data":{},"marks":[],"value":" für rund 2,2 Milliarden US-Dollar. Das sind rund zehn Milliarden US-Dollar in wenigen Wochen. ","nodeType":"text"}],"nodeType":"paragraph"},{"data":{},"content":[{"data":{},"marks":[{"type":"bold"}],"value":"Jetzt könnte man meinen:","nodeType":"text"},{"data":{},"marks":[],"value":" ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Gilead","nodeType":"text"},{"data":{},"marks":[],"value":" ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Sciences","nodeType":"text"},{"data":{},"marks":[],"value":" mit einem Aktienkurs nahe Rekordniveau, einer Marktkapitalisierung von 166 Milliarden US-Dollar und seiner robusten Bilanz stellt sich breiter auf. Bisher hatte das Unternehmen einen Fokus auf HIV-Therapien. Jetzt kommen Onkologie und Autoimmunerkrankungen hinzu.","nodeType":"text"}],"nodeType":"paragraph"},{"data":{"target":{"metadata":{"tags":[],"concepts":[]},"sys":{"id":"75wgVVjxvQjjfniGIbIcl8","type":"Entry","createdAt":"2026-04-01T14:14:33.112Z","updatedAt":"2026-04-01T14:15:16.402Z","publishedVersion":3,"revision":2,"contentType":{"sys":{"type":"Link","linkType":"ContentType","id":"infoGraphic"}},"locale":"de"},"fields":{"title":"Gilead Sciences: Auf Rekordkurs","description":"Aktienkursentwicklung von Gilead Sciences seit 5 Jahren","media":{"sys":{"type":"Link","linkType":"Entry","id":"6koDgRtl0dJGM1uC8z70Fp"},"fields":{"id":"SW1hZ2VXaXRoTWV0YS02a29EZ1J0bDBkSkdNMXVDOHo3MEZwX19fMzIzMjE3ZjY0M2MzZTNmMWZlNzUzMmU3MmFjMDFiYjA3NDhjOTdiZQ","url":"https://image-service.thepioneer.de/show/mj324dykhxwi/5jbJEaZM7A4A3NSqLJywYJ/f6fc7f0aebede8c5134efaf719301cb9/Gilead_Sciences_Auf_Rekordkurs_no_header.png","preview":"","width":1850,"height":2165,"assetId":"5jbJEaZM7A4A3NSqLJywYJ","link":null,"title":"Gilead Sciences: Auf Rekordkurs","fileSize":1544229,"contentType":"image/png"}},"slug":"gilead-sciences-auf-rekordkurs-cossap","download":{"metadata":{"tags":[],"concepts":[]},"sys":{"space":{"sys":{"type":"Link","linkType":"Space","id":"mj324dykhxwi"}},"id":"4fNI0NgXuuJ9gownWfIQCE","type":"Asset","createdAt":"2026-04-01T14:14:27.847Z","updatedAt":"2026-04-01T14:14:27.847Z","environment":{"sys":{"id":"master","type":"Link","linkType":"Environment"}},"publishedVersion":2,"revision":1,"locale":"de"},"fields":{"title":"Gilead Sciences: Auf Rekordkurs","file":{"url":"//images.ctfassets.net/mj324dykhxwi/4fNI0NgXuuJ9gownWfIQCE/98a45efa1bc95a3907f311fa850b5f6f/Gilead_Sciences_Auf_Rekordkurs_with_header.png","details":{"size":1174987,"image":{"width":1600,"height":2132}},"fileName":"Gilead_Sciences_Auf_Rekordkurs_with_header.png","contentType":"image/png"}}},"tags":[{"metadata":{"tags":[],"concepts":[]},"sys":{"space":{"sys":{"type":"Link","linkType":"Space","id":"mj324dykhxwi"}},"id":"kfFDMkIMIwjSP4rAejdw6","type":"Entry","createdAt":"2026-04-01T06:54:37.192Z","updatedAt":"2026-04-01T06:54:37.192Z","environment":{"sys":{"id":"master","type":"Link","linkType":"Environment"}},"publishedVersion":1,"revision":1,"contentType":{"sys":{"type":"Link","linkType":"ContentType","id":"tag"}},"locale":"de"},"fields":{"title":"Gilead Sciences"}},{"metadata":{"tags":[],"concepts":[]},"sys":{"space":{"sys":{"type":"Link","linkType":"Space","id":"mj324dykhxwi"}},"id":"5k8eBTybSeO8eAYZSTlBlf","type":"Entry","createdAt":"2023-12-18T16:22:52.119Z","updatedAt":"2023-12-18T16:22:52.119Z","environment":{"sys":{"id":"master","type":"Link","linkType":"Environment"}},"publishedVersion":1,"revision":1,"contentType":{"sys":{"type":"Link","linkType":"ContentType","id":"tag"}},"locale":"de"},"fields":{"title":"Aktienkursentwicklung"}},{"metadata":{"tags":[],"concepts":[]},"sys":{"space":{"sys":{"type":"Link","linkType":"Space","id":"mj324dykhxwi"}},"id":"5zUr0JxoyYzpyYdN7nz09P","type":"Entry","createdAt":"2023-12-18T16:21:09.060Z","updatedAt":"2023-12-18T16:21:09.060Z","environment":{"sys":{"id":"master","type":"Link","linkType":"Environment"}},"publishedVersion":1,"revision":1,"contentType":{"sys":{"type":"Link","linkType":"ContentType","id":"tag"}},"locale":"de"},"fields":{"title":"Biotechnologie"}},{"metadata":{"tags":[],"concepts":[]},"sys":{"space":{"sys":{"type":"Link","linkType":"Space","id":"mj324dykhxwi"}},"id":"1eblFrk5McKmEDsWkXDEDN","type":"Entry","createdAt":"2023-12-18T16:10:50.351Z","updatedAt":"2023-12-18T16:10:50.351Z","environment":{"sys":{"id":"master","type":"Link","linkType":"Environment"}},"publishedVersion":1,"revision":1,"contentType":{"sys":{"type":"Link","linkType":"ContentType","id":"tag"}},"locale":"de"},"fields":{"title":"Pharmaunternehmen"}},{"metadata":{"tags":[],"concepts":[]},"sys":{"space":{"sys":{"type":"Link","linkType":"Space","id":"mj324dykhxwi"}},"id":"2vziSV5nVpD9f9ZE5grX3Y","type":"Entry","createdAt":"2020-05-07T11:30:24.828Z","updatedAt":"2020-05-07T11:30:24.828Z","environment":{"sys":{"id":"master","type":"Link","linkType":"Environment"}},"publishedVersion":5,"revision":1,"contentType":{"sys":{"type":"Link","linkType":"ContentType","id":"tag"}},"locale":"de"},"fields":{"title":"Rekordkurs"}}],"publishingDate":"2026-04-01T14:14:31.730Z","id":"SW5mb0dyYXBoaWMtNzV3Z1ZWanh2UWpqZm5pR0liSWNsOA"}}},"content":[],"nodeType":"embedded-entry-block"},{"data":{},"content":[{"data":{},"marks":[{"type":"bold"}],"value":"Doch das kaschiert die Dramatik:","nodeType":"text"},{"data":{},"marks":[],"value":" Diese Deals sind keine Kür, sondern Pflicht. ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Gilead Sciences","nodeType":"text"},{"data":{},"marks":[],"value":" verschiebt Kapital aus einem reifen, extrem profitablen Geschäft in eine Zukunft, die erst noch bewiesen werden muss. ","nodeType":"text"}],"nodeType":"paragraph"},{"data":{},"content":[{"data":{},"marks":[],"value":"Das bestehende Geschäft wächst kaum noch. 2025 stieg der Umsatz auf 29,4 Milliarden US-Dollar. Das war ein Plus von zwei Prozent. Die Produktumsätze legten sogar nur um ein Prozent auf 28,9 Milliarden US-Dollar zu. ","nodeType":"text"}],"nodeType":"paragraph"},{"data":{},"content":[{"data":{},"marks":[],"value":"Das schrumpfende Covid-Medikament ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Veklury ","nodeType":"text"},{"data":{},"marks":[],"value":"herausgerechnet, sieht das Bild etwa besser aus. Dann liegt das Wachstum des Basisgeschäfts bei immerhin vier Prozent. Aber auch das ist für einen Pharmakonzern nicht genug, um die Zukunft allein organisch zu finanzieren.","nodeType":"text"}],"nodeType":"paragraph"},{"data":{},"content":[{"data":{},"marks":[{"type":"bold"}],"value":"Die Analyse zeigt:","nodeType":"text"},{"data":{},"marks":[],"value":" ","nodeType":"text"},{"data":{},"marks":[{"type":"italic"}],"value":"Gilead Sciences","nodeType":"text"},{"data":{},"marks":[],"value":" ist eine Kapitalallokationsmaschine unter Zeitdruck. ","nodeType":"text"}],"nodeType":"paragraph"}],"nodeType":"document"}

Autoren